FDA Approves Vision-Enhancing Implantable Telescope for AMD
The IMT provides improved central and detailed vision by focusing and magnifying images onto the functional, outer regions of the recipient’s retina. People with advanced AMD normally experience degeneration of the macula or central region of the retina.
In clinical studies, the device has helped people improve their ability to read, recognize faces, and perform other detailed-oriented tasks. In a 219-participant study, 75 percent of recipients had their level of vision improved from severe impairment to moderate impairment.
Through a surgical procedure, the IMT replaces a recipient’s existing lens. The IMT is only placed into one eye. A recipient’s other eye is used for peripheral vision.
The FDA notes that there is a risk of short- and long-term corneal swelling and damage from the device. The cornea is the transparent cover of the front of the eye, and when damaged, can cause a decrease in vision.
Recipients must undergo testing and training to determine if they will benefit from the IMT.
“The IMT is a beneficial development for some people with end-stage AMD, who have no other treatment options,” says Stephen Rose, Ph.D., chief research officer, Foundation Fighting Blindness. “While not a treatment or a cure, the IMT can provide meaningful vision improvement for the right candidates.”
The IMT was developed by VisionCare Ophthalmic Technologies. To learn more about the device and whether you may be a candidate for receiving it, visit www.visioncareinc.net or contact your retinal specialist or ophthalmologist.